Author

Martin J. Glennie

Observed names: M Glennie, M J Glennie, M. Glennie, M. J. GLENNIE, M. J. Glennie, M.J. GLENNIE, M.J. Glennie, MARTIN GLENNIE, MARTIN J. GLENNIE, MJ Glennie, Martin Glennie, Martin J Glennie, Martin?J. Glennie, Martin J. Glennie, Martin J. Glennie

Institution: University of Southampton

Observed institutions: Mayo Clinic, Friedrich-Alexander-Universität Erlangen-Nürnberg, Utrecht University, Royal Bournemouth Hospital, Cancer Research UK, Southampton General Hospital, University Hospital Southampton NHS Foundation Trust, University Medical Center Utrecht, University of Warwick, Genmab (Netherlands), Tenovus Cancer Care, NIHR CRUK Experimental Cancer Medicine Centre, University of Southampton, University College London, Medical Research Council, University of Wales

ORCID: 0000-0001-8962-5901

Observed ORCID: 0000-0001-8962-5901

OpenAlex ID: A5074087478

Immunostimulatory monoclonal antibodies for cancer therapy

2007 · Ignacio Melero, Sandra Hervas-Stubbs, et al. · Nature reviews. Cancer · 627

The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20

2006 · Jessica L Teeling, Wendy J M Mackus, et al. · The Journal of Immunology · 609

Mechanisms of killing by anti-CD20 monoclonal antibodies

2007 · Martin J. Glennie, Ruth R. French, et al. · Molecular Immunology · 515

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

1999 · Ruth R. French, H.T. Claude Chan, et al. · Nature Medicine · 426

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

2003 · Mark S. Cragg, Suzanne M. Morgan, et al. · Blood · 390

The Biology of CD20 and Its Potential as a Target for mAb Therapy

2004 · Mark S. Cragg, Claire A. Walshe, et al. · KARGER eBooks · 364

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

2003 · Mark S. Cragg, Martin J. Glennie · Blood · 360

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

2010 · Stephen A. Beers, Ruth R. French, et al. · Blood · 335

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

2011 · Waleed Alduaij, Andrei Ivanov, et al. · Blood · 294

PDF

Clinical trials of antibody therapy

2000 · Martin J Glennie, Peter W.M Johnson · Immunology Today · 290

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

2011 · Sean H. Lim, Andrew T. Vaughan, et al. · Blood · 267

PDF

The mechanisms of action of rituximab in the elimination of tumor cells

2003 · Peter Johnson, Martin Glennie · Seminars in Oncology · 247

Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

2011 · Ann L White, H T Claude Chan, et al. · The Journal of Immunology · 226

PDF

CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts.

2003 · H T Claude Chan, David Hughes, et al. · PubMed · 211

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies

2010 · Stephen A. Beers, Claude H.T. Chan, et al. · Seminars in Hematology · 209

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples

2017 · Venkat Reddy, Christian Klein, et al. · Lara D. Veeken · 205

PDF

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

2008 · Stephen A. Beers, Claude H. T. Chan, et al. · Blood · 180

PDF

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells

2009 · Andrei Ivanov, Stephen A. Beers, et al. · Journal of Clinical Investigation · 177

PDF

Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies

2014 · Ann L. White, H.T. Claude Chan, et al. · Cancer Cell · 173

PDF

Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function

2018 · Sarah L. Buchan, Lang Dou, et al. · Immunity · 160

PDF

Renaissance of cancer therapeutic antibodies

2003 · Martin J. Glennie, Jan G.J. van de Winkel · Drug Discovery Today · 155

Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses

2002 · Vadim?Y. Taraban, Tania?F. Rowley, et al. · European Journal of Immunology · 150

PDF

Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling

2008 · Claire A. Walshe, Stephen A. Beers, et al. · Journal of Biological Chemistry · 145

Systemic Inflammation Modulates Fc Receptor Expression on Microglia during Chronic Neurodegeneration

2011 · Katie Lunnon, Jessica L Teeling, et al. · The Journal of Immunology · 138

Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo

2015 · Ali Roghanian, Ingrid Teige, et al. · Cancer Cell · 136

PDF

Works count: 239

Citation count: 13,220

H-index: 64

I10-index: 137